Sinovac Biotech Ltd (SVA)

[surf1944]

6:32AM Sinovac Biotech's EV71 Vaccine Phase I clinical data for the prevention of Epidemic Hand, Foot, Mouth disease published in Vaccine says 'trial showed that Sinovac's novel inactivated human EV71 vaccine was well tolerated in healthy volunteers' (SVA) 2.02 : Co announced that the positive Phase I clinical data for its proprietary inactivated Enterovirus 71 vaccine against hand, foot and mouth disease was accepted for publication by the peer-reviewed journal Vaccine on March 4, 2012, and the uncorrected proof is available online as of March 14, 2012. The Phase I clinical trial showed that Sinovac's novel inactivated human EV71 vaccine was well tolerated in healthy volunteers, and the testing results on neutralizing antibody indicated good immunogenicity. Sinovac confirmed these data in the Phase II trial, which demonstrated that the EV71 vaccine demonstrated a good immunogenicity and a favorable safety profile with no vaccine-related serious adverse events. Co stated "Meanwhile, the construction of the EV71 vaccine production plant is progressing well. The purpose of building the facility in parallel with the Phase III clinical research is to make sure that the vaccine can be provided to protect those at risk as soon as it's approved."